Features
Genome Editing and Gene Therapy to Treat Angiogenesis
New developments have the potential to change the way retina specialists treat disease.
By Michael J. Ammar, MD, Julia A. Haller, MD
Choroidal Melanoma or Peripheral Exudative Hemorrhagic Chorioretinopathy
Imaging is critical to this diagnostic dilemma.
By Guneet S. Sodhi, MD, Brittney Statler, MD, Arun D. Singh, MD
Pearls for Pediatric Retinal Diseases
Five pearls for five diseases.
By Luis A. Acaba-Berrocal, MD, R.V. Paul Chan, MD, MSc, MBA, FACS, Audina M. Berrocal, MD
A 2020 Update on Vitrectomy Systems
Retina specialist users discuss their experience with various platforms.
By BRIAN JOONDEPH, MD, MPS, FACS, Martin Charles, MD, Dina Abulon, MS, et al.
Cryopreserved Amniotic Membrane for Intravitreal Injection
Take steps to ease injection-associated stress and boost adherence.
By Atul Jain, MD
A Current Perspective on Intraocular Pressure Elevation in Chronic Noninfectious Uveitis
Monitoring protocols are key to preserving vision.
By Michael A. Singer, MD
Web Exclusives
Future Therapies in Uveitis
Novel methods are growing the armamentarium for treating this complex ocular disease.
By Jordan D. Deaner, MD, Sumit Sharma, MD
Departments
UPFRONT: Gene Editing for Retina Is Approaching
By Peter K. Kaiser, MD
FUTURE FILE: Highlighting innovative early-stage and preclinical concepts in retina
By Jerry Helzner, contributing editor
CLINICAL TRIAL DOWNLOAD: Macular Atrophy Lesion Change With an Anti-VEGF Implant
Retina specialists discuss an analysis of LADDER trial data.
By Yasha Modi, MD , Nitish Mehta, MD, Michael A. Singer, MD, et al.
NEW PRODUCT APPLICATIONS: Artificial Intelligence Brings DR Screening Beyond Eye-Care Practices
A new device achieves autonomous detection of vision-threatening diabetic retinopathy.
CODING Q&A: The Whys and Whens of Billing for Screening Tests
The intent governs the designation of screening or medical necessity.
By Suzanne L. Corcoran, COE
News
OpRegen Cell Therapy Has Positive Data in Geographic Atrophy
Visual acuity gains were maintained up to 24 months.
By Jerry Helzner, contributing editor
Gemini Geographic Atrophy Drug to Advance Into Phase 2 Trial
Recombinant form of complement factor H met phase 1 endpoints.
By Jerry Helzner, contributing editor
Wet AMD Patients Prefer PDS Implant Over Injections
Patients underwent only 2 procedures in 40 weeks.
By Jerry Helzner, contributing editor
Suprachoroidal Drug Delivery Scores Well in Study
Physician users report the administration technique to be applicable to a range of anatomic and demographic variables.
By Jerry Helzner, contributing editor
IRIS Registry Study Shows Severe Impact of Geographic Atrophy
Data show that vision loss is often dramatic.
By Jerry Helzner, contributing editor
Adverum Gene-derived Anti-VEGF Proves Highly Durable
Wet AMD patient goes 92 weeks without retreatment.
By Jerry Helzner, contributing editor
SUBSPECIALTY NEWS: Bausch Health takes option for Allegro, phase 3 trials begin for KSI-301, and more.
By Jerry Helzner, contributing editor
Supplements
The Retina Counselor
Emerging treatments for diabetic eye diseases
By Avni Finn, MD, MBA, Mrinali Gupta, MD